Advertisement

Topics

Latest Immunization NewsRSS

22:50 EDT 23rd May 2018 | BioPortfolio

AHF to WHO: Ebola History Cannot be Repeated

AHF calls on the Director-General of the World Health Organization (WHO), Dr. Tedros Adhanom Ghebreyesus, and Deputy Director-General of Emergency Preparedness and Response, Dr. Peter Salama, to expedite delivery of Ebola vaccine to Democratic Republic of Congo (DRC), where latest outbreak has claimed 27 lives to date. Ebola is back and the world is...

Excitement over use of Ebola vaccine in outbreak tempered by real-world challenges

There are challenges ahead in the real-world use of the Ebola vaccine the DRC, warned the head of the global health organization that is funding the current vaccination effort.

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine and plans to launch a Phase III study next year. British biotech Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine. ... The post Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results appeared first on Labiotech.eu.

Ebola Update: Funding, Vaccines, and More Deaths in DRC

A total of 27 people have died since April, but new funds and the deployment of an experimental vaccine are expected to help contain the virus.

Biotech Announces Encouraging HIV Vaccine Results

May 23, 2018 (Investorideas.com Newswire) Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained the recently released data from a study of one of this immunotherapy firm's therapeutics.

A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+

Study Finds Prevnar 13 was Associated With Reduced Risk of Hospitalization From Vaccine-Type Community-Acquired Pneumonia in Older Adults1 Pfizer Inc. (NYSE: PFE) announced today that results from a study analyzing real-world effectiveness data found that Prevnar 13® (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 Protein]) reduced...

Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine

RSV affects 33 million children globally and leads to approximately 120,000 childhood deaths every year1 In the United States approximately 177,000 older adults are hospitalized annually because of RSV2 The clinical program aims to develop a vaccine for populations at highest risk of infection: infants through maternal immunization, and ...

‘You’re holding your breath’: Scientists who toiled for years on an Ebola vaccine see the first one put to the test

The Ebola vaccine being fielded in the latest outbreak is the product of years of striving against skepticism and disinterest.

Pediatrics Group Recommends Flu Shot over Nasal Spray for Upcoming Flu Season

The American Academy of Pediatrics said on Monday that it will recommend the injectable influenza vaccine over the live attenuated flu vaccine (nasal spray marketed...

#news #biotech ImmusanT goes on hiring spree ahead of phase 2 celiac vaccine trial

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: ImmusanT goes on hiring spree ahead of phase 2 celiac vaccine trial .ImmusanT is boosting its senior staff, bringing on Daiichi Sankyo’s SVP for internal medicine therapeutics, Ken … Continue reading → Cet article #news #biotech ImmusanT goes on hiring spree ahea...

NIH Awards Grant to Lumen Bioscience for Cost-Effective Oral Malaria Vaccine

The post NIH Awards Grant to Lumen Bioscience for Cost-Effective Oral Malaria Vaccine appeared first on SynBioBeta.

GC Pharma to Establish Curevo - a Seattle-based New Company Dedicated to Development of New Vaccines

GC Pharma, IDRI and MIBR Bringing Together to Develop Innovative Vaccines YONGIN, South Korea, May 20, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced the establishment of Curevo Inc. ("Curevo"). The newly established Seattle-based company's goal...

HIV Vaccine Awareness: 2018 Has So Far Seen the Approval of Three New HIV Drugs

As another HIV Vaccine Awareness Day slides by on the calendar, there is still no cure for the disease. However, many pharma and biotech companies are desperately working on developing therapeutics for the devastating disease.

Your NEJM Group Today: Nausea, Vomiting, Confusion Case / HPV Vaccine-Hesitant Parents / N.M. Oncology Opportunity

Take a peek at some of the latest, greatest content from NEJM Group: NEJM Primary Care/Hospitalist Page: Case record: An 83-year-old woman...

What Is the Most Effective Response to HPV Vaccine–Hesitant Parents?

Provider persistence in explaining vaccine rationale to parents was the most effective approach to achieving same-day HPV vaccination.

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Revision: 30, Authorised

Creative Diagnostics Launches Adjuvant for Life Science Researchers

As a leading supplier of products and services in antibody development, immunoassay and diagnosis, Creative Diagnostics announces that it has added Magic™ adjuvant to its existing products portfolio. The Magic™ adjuvants are highly efficient, biocompatible, convenient and economical, which have become the gold standard references for any immunization experiments....

Flu Mandates: Consider Accommodations and Avoid a Lawsuit

Mandated influenza vaccination programs for healthcare workers have proved highly effective at raising immunization rates, but hospitals that fail to navigate religious exemptions have found themselves on the wrong end of court rulings.

Fauci: HIV Can Be Stopped, but Vaccine Remains Elusive

One of the great pandemics in human history has been fought to a near draw, with no vaccine in sight but treatments that dramatically extend life and block transmission to others.

Biopharma, Regulators and Researchers Turn Their Focus to Universal Flu Vaccines

The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.

Bavarian Nordic to Host First Quarter 2018 Results Conference Call

COPENHAGEN, Denmark - May 16, 2018 - Bavarian Nordic A/S (OMX:  BAVA, OTC: BVNRY) will announce its 2018 first quarter results on Thursday, May 24, 2018. The management of Bavarian Nordic will host a conference call at 2:00 pm CEST (8:00 am EDT) on the same day to present the interim results followed by a Q&A session. A live and replay version of the call and relevant slides will...

Veterinary medicine European public assessment report (EPAR): BTVPUR Alsap 8, adjuvanted bluetongue virus vaccine, Revision: 5, Withdrawn

Multi-epitope T-cell Vaccine Shows Promise in Ovarian, Breast Cancer

TPIV200 stimulates T cells to attack ovarian and triple negative breast tumor cells that over-express the folate receptor alpha protein.

FluGen Begins Enrollment of Clinical Trial of Novel Investigational Influenza Vaccine Against Multi-Season Mismatched Strains

—Investigational vaccine designed to generate broad and durable immune protection over multiple influenza seasons— —Subjects challenged with influenza virus genetically drifted by six years from vaccine strain— —Study supported by U.S. Department of Defense— FluGen, Inc. announced today that the first subject has...

Human medicines European public assessment report (EPAR): Trumenba, meningococcal group b vaccine (recombinant, adsorbed), Revision: 3, Authorised

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Immunization market research data and corporate reports here